Table 2. Association of STK3 rs7827435 with BCR in localized prostate cancer patients treated with RP.

	Univariate analysis										Multivariate analysisa
Gene SNP	Discovery				Replication				Combined		Discovery		Replication		Combined
Genotype	No BCR	BCR	HR (95% CI)	P	No BCR	BCR	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
STK3 rs7827435
AA	40	23	1.00		25	29	1.00		1.00		1.00		1.00		1.00
AT	87	38	0.80 (0.47–1.34)	0.387	53	59	1.10 (0.70–1.72)	0.690	0.96 (0.68–1.36)	0.83	0.93 (0.54–1.59)	0.785	0.90 (0.57–1.41)	0.635	0.91 (0.64–1.29)	0.61
TT	40	12	0.49 (0.25–0.99)	0.048	24	16	0.60 (0.32–1.10)	0.097	0.55 (0.34–0.86)	0.01	0.43 (0.20–0.89)	0.024	0.49 (0.26–0.93)	0.028	0.46 (0.29–0.76)	0.002
AT/TT vs AA			0.69 (0.42–1.14)	0.147			0.93 (0.60–1.42)	0.725	0.82 (0.59–1.13)	0.23	0.73 (0.44–1.21)	0.220	0.76 (0.49–1.18)	0.220	0.75 (0.54–1.04)	0.08
TT vs AA/AT			0.57 (0.31–1.07)	0.079			0.56 (0.33–0.96)	0.034	0.56 (0.38–0.84)	0.005	0.45 (0.23–0.87)	0.018	0.53 (0.30–0.93)	0.026	0.49 (0.32–0.76)	0.001
Trend			0.72 (0.52–1.00)	0.048			0.81 (0.62–1.07)	0.133	0.77 (0.63–0.95)	0.01	0.70 (0.50–0.97)	0.030	0.73 (0.55–0.98)	0.033	0.72 (0.58–0.89)	0.003

Abbreviations: BCR, biochemical recurrence; RP, radical prostatectomy; SNP, single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.

^aAdjusted by age, PSA at diagnosis, pathologic Gleason score, and pathologic stage.

P < 0.05 are in boldface.